Clinical Trial Update: A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) [Phase 4]

View source ↗

Summary

Phase 4 trial MK-3475-B10 (KEYNOTE B10) evaluating pembrolizumab with carboplatin and paclitaxel as first-line therapy for recurrent/metastatic head and neck sq…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 4 | Status: COMPLETED | Results posted: 2024-05-09